West Pharmaceutical Services, Inc. (WST) Financial Statements

Executive TeamFinancials
SegmentsShareholders

West Pharmaceutical Services financial statements at a glance

West Pharmaceutical Services reported revenue of $3.07 billion for fiscal year 2025 (ended December 31, 2025), up 6.3% from fiscal year 2024. Net income was $493.70 million, a net margin of 16.1%, and diluted earnings per share were $6.79.

At the end of fiscal year 2025 it had total assets of $4.27 billion, total liabilities of $1.09 billion and shareholders' equity of $3.18 billion, with cash and short-term investments of $791.30 million and total debt of $321.10 million.

Its operations brought in $754.80 million of cash; capital spending was $285.90 million, leaving free cash flow of $468.90 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

WST logo

West Pharmaceutical Services, Inc.

WSTUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
3.07B
Prev Year: 2.89B
YoY: +6.3%
Operating Revenue
3.07B
Prev Year: 2.89B
YoY: +6.3%
Tax Effect of Unusual Items
-10.08M
Prev Year: -3.70M
YoY: -172.5%
Total Unusual Items
-49.90M
Prev Year: -20.10M
YoY: -148.3%
Total Unusual Items Excluding Goodwill
-49.90M
Prev Year: -20.10M
YoY: -148.3%
Interest Income
17.50M
Prev Year: 19.60M
YoY: -10.7%
Equity in Earnings of Affiliates, Net of Tax
14.40M
Prev Year: 14.70M
YoY: -2.0%
Other Income Expense
-52.20M
Prev Year: -22.00M
YoY: -137.3%
Other Non-operating Income (expense)
-2.30M
Prev Year: -1.90M
YoY: -21.1%
Special Income Charges
-41.50M
Prev Year: -9.90M
YoY: -319.2%
Write-offs
4.50M
Prev Year: 7.30M
YoY: -38.4%
Impairment of Capital Assets
3.70M
Restructuring and Mergers Acquisition
33.30M
Prev Year: 2.60M
YoY: +1180.8%
Gain on Sale of Securities
-8.40M
Prev Year: -10.20M
YoY: +17.6%
Non-operating Interest Income
17.50M
Prev Year: 19.60M
YoY: -10.7%
Cost of Revenue
1.97B
Prev Year: 1.89B
YoY: +4.0%
Gross Profit
1.10B
Prev Year: 998.50M
YoY: +10.6%
Operating Expense
467.90M
Prev Year: 407.60M
YoY: +14.8%
Selling General and Administrative
393.60M
Prev Year: 338.50M
YoY: +16.3%
Research and Development
74.30M
Prev Year: 69.10M
YoY: +7.5%
Operating Income
636.10M
Prev Year: 590.90M
YoY: +7.6%
Net Non Operating Interest Income Expense
17.00M
Prev Year: 16.60M
YoY: +2.4%
Pre-tax Income
600.90M
Prev Year: 585.50M
YoY: +2.6%
Provision for Income Taxes
121.60M
Prev Year: 107.50M
YoY: +13.1%
Net Income Common Stockholders
493.70M
Prev Year: 492.70M
YoY: +0.2%
Net Income
493.70M
Prev Year: 492.70M
YoY: +0.2%
Net Income Including Non-Controlling Interests
493.70M
Prev Year: 492.70M
YoY: +0.2%
Net Income from Continuing Operations
493.70M
Prev Year: 492.70M
YoY: +0.2%
Diluted NI Available to Com Stockholders
493.70M
Prev Year: 492.70M
YoY: +0.2%
Basic EPS
6.83
Prev Year: 6.75
YoY: +1.2%
Diluted EPS
6.79
Prev Year: 6.69
YoY: +1.5%
Weighted Average Shares (basic)
72.30M
Prev Year: 73.00M
YoY: -1.0%
Weighted Average Shares (diluted)
72.70M
Prev Year: 73.70M
YoY: -1.4%
Total Operating Income as Reported
584.90M
Prev Year: 569.90M
YoY: +2.6%
Total Expenses
2.44B
Prev Year: 2.30B
YoY: +5.9%
Net Income from Continuing and Discontinued Operation
493.70M
Prev Year: 492.70M
YoY: +0.2%
Normalized Income
533.52M
Prev Year: 509.10M
YoY: +4.8%
Interest Expense
500.0K
Prev Year: 3.00M
YoY: -83.3%
Net Interest Income
17.00M
Prev Year: 16.60M
YoY: +2.4%
EBITDA
772.80M
Prev Year: 743.90M
YoY: +3.9%
Reconciled Cost of Revenue
1.97B
Prev Year: 1.89B
YoY: +4.0%
Reconciled Depreciation
171.40M
Prev Year: 155.40M
YoY: +10.3%
Net Income from Continuing Operation Net Minority Interest
493.70M
Prev Year: 492.70M
YoY: +0.2%
EBIT
-
Prev Year: 588.50M
Normalized EBITDA
822.70M
Prev Year: 764.00M
YoY: +7.7%
Tax Rate for Calcs
0.202
Prev Year: 0
Values in USD

West Pharmaceutical Services key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$3.1B$2.9B$2.9B$2.9B$2.8B
Gross profit$1.1B$998.5M$1.1B$1.1B$1.2B
Operating income$636.1M$590.9M$707.4M$760.8M$760.2M
Net income$493.7M$492.7M$593.4M$585.9M$661.8M
Diluted EPS$6.79$6.69$7.88$7.73$8.67
Total assets$4.3B$3.6B$3.8B$3.6B$3.3B
Total liabilities$1.1B$961.1M$948.5M$931.9M$978.4M
Shareholders' equity$3.2B$2.7B$2.9B$2.7B$2.3B
Cash and short-term investments$791.3M$484.6M$853.9M$894.3M$762.6M
Total debt$321.1M$302.3M$309.0M$317.9M$325.3M
Operating cash flow$754.8M$653.4M$776.5M$724.0M$584.0M
Capital spending$285.9M$377.0M$362.0M$284.6M$253.4M
Free cash flow$468.9M$276.4M$414.5M$439.4M$330.6M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was West Pharmaceutical Services's revenue in fiscal year 2025?

$3.07 billion, up 6.3% from $2.89 billion in fiscal year 2024.

How much profit does West Pharmaceutical Services make?

West Pharmaceutical Services reported net income of $493.70 million for fiscal year 2025 (16.1% of revenue); operating income was $636.10 million.

How much cash and debt does West Pharmaceutical Services have?

At the end of fiscal year 2025: cash and short-term investments of $791.30 million and total debt of $321.10 million.

What is West Pharmaceutical Services's free cash flow?

$468.90 million in fiscal year 2025 (operating cash flow of $754.80 million minus capital spending of $285.90 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube